Boehringer Ingelheim Pharmaceuticals, Inc., manufacturer of Pradaxa, has agreed to pay $650 million to settle Pradaxa lawsuits filed on behalf of approximately 4,000 injured plaintiffs. Managing partner Ramon Lopez serves on the Plaintiffs Steering Committees both for the Illinois Multi District Litigation and the California State Coordinated Actions. Mr. Lopez played an important role in the pretrial and discovery proceedings that led to the settlement agreement, and helped to negotiate the settlement on behalf of ...
continue reading...$650 Million Settlement in Pradaxa Lawsuit
Posted June 13, 2014 in Benicar | Drug and Medical Device Lawsuits | Pradaxa Internal Bleeding | Product News and Recalls | Verdicts & Settlements
A Thalidomide lawsuit involving over one hundred people form Australia and New Zealand and settled according to news sources. Thalidomide was a prescription drug marketed and sold in the 1950s but was pulled from the market when it was linked to causing thousands of babies to be born with deformities. The British company Diageo, who now owns the firm that originally distributed Thalidomide, agreed to the settlement that is valued at approximately $81 million that will compensate the ...
continue reading...Dietary Supplement OxyELITE Pro Linked to Liver Failure
Posted October 18, 2013 in Pradaxa Internal Bleeding | Product News and Recalls
Numerous media outlets are reporting that USP Labs, the manufacturer of the dietary supplement and popular diet pill, OxyELITE Pro has stopped nationwide distribution of its product following numerous cases of liver failure being linked to the supplement.
The FDA has advised consumers to stop using any dietary supplement that is labeled OxyELITE Pro as it investigates. The Center for Disease Control and Prevention (CDC) and ...
continue reading...Pradaxa Linked with Increased Risk of Gastrointestinal Bleeding
Posted August 28, 2013 in Pradaxa Internal Bleeding | Product News and Recalls
A new study shows the use of the anti-coagulant known as Pradaxa is associated with a significant increase in the risk of gastrointestinal bleeding. The increased risk is compared to traditional or standard treatment with drugs such as enoxaparin, warfarin, antiplatelet therapy, or no therapy (placebo).
The study analyzed 17 randomized controlled trails and found an increased risk for gastrointestinal bleeding for patients taking newer anti-coagulants versus the more traditional treatments. Although there was a ...
continue reading...Officials See Rise in Emergency Room Visits Related to Prescription Stimulant Use
Posted August 20, 2013 in Byetta/Januvia Pancreatic Cancer | Lipitor | Pradaxa Internal Bleeding | Product News and Recalls
A recent NY Times article discusses a recent trend that shows an increase in the number of emergency room visits as a result of the use of prescription stimulants such as Adderall and Ritalin. According to data gathered by the Substance Abuse and Mental Health Services Administration, a branch of the Department of Health and Human Services, emergency rooms have seen a dramatic increase in the number of visits related to prescription stimulants.
The number of emergency room visits ...
continue reading...Doctor says blood thinner carries risks
Posted March 2, 2013 in Pradaxa Internal Bleeding | Product News and Recalls
In a column in the Spokesman-Review out of Washington, Dr. Anthony L. Komaroff, M.D., answers a letter-writer’s question about the blood-thinner Pradaxa.
The letter-writer says his wife has atrial fibrillation, and her medication was recently changed from warfarin to Pradaxa. He wants to know if she’s right in claiming that the medicine is just as effective, although it requires fewer tests.
Komaroff writes that technically, Pradaxa is just as effective in preventing blood clots. But Pradaxa presents some risks that warfarin, the ...
continue reading...
